{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034430","form_type":"8-K","ticker":"ALUR","cik":"0001964979","company_name":"ALLURION TECHNOLOGIES, INC.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.389352+00:00","generated_at":"2026-06-04T10:35:57.312309+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Allurion Q4 2023 revenue drops to $8.2M from $19.2M; operating loss widens to $25.7M","bullets":["Q4 2023 revenue $8.2M (down 57% YoY); full year 2023 revenue $53.5M.","Q4 operating loss $25.7M vs $10.1M in Q4 2022, driven by $7M AR reserves and $3M stock comp.","Cash and equivalents $38M at Dec 31, 2023; targeting ~$30M cash burn for 2024.","Reiterates 2024 guidance: revenue $60-65M, 20% procedural volume growth, 77-79% gross margins.","Completed AUDACITY pivotal trial enrollment for FDA PMA; first UK NHS reimbursed patients treated."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034430","json":"https://secwatch.observer/filing/0000950170-24-034430.json","markdown":"https://secwatch.observer/filing/0000950170-24-034430.md","text":"https://secwatch.observer/filing/0000950170-24-034430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1964979/000095017024034430/0000950170-24-034430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1964979/000095017024034430/alur-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:35:57.312309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}